These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33237474)

  • 1. New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19 : In Responding to a Global Health Crisis, Industry is Discovering New, Efficient Ways of Meeting Objectives.
    Wegner M
    Ther Innov Regul Sci; 2021 Mar; 55(2):463-466. PubMed ID: 33237474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Utility of Remote Inspections During the COVID-19 Health Emergency and in the Postpandemic Setting.
    Mofid S; Bolislis WR; Brading C; Hamilton N; Hardit C; Nagaoka M; Parain J; Zanta M; Kühler TC
    Clin Ther; 2021 Dec; 43(12):2046-2063. PubMed ID: 34740466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation.
    Lee M; Ly H; Möller CC; Ringel MS
    Clin Pharmacol Ther; 2019 Apr; 105(4):886-898. PubMed ID: 30636288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reacting to crises: The COVID-19 impact on biostatistics/epidemiology.
    O'Neill RT
    Contemp Clin Trials; 2021 Mar; 102():106214. PubMed ID: 33186685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond.
    Furtner D; Shinde SP; Singh M; Wong CH; Setia S
    Pharmaceut Med; 2022 Feb; 36(1):1-10. PubMed ID: 34970723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pandemic and resilience for the future: AccBio 2021.
    McGovern ĀT; Salisbury CM; Nyberg GB
    Biotechnol Prog; 2022 Jan; 38(1):e3207. PubMed ID: 34463436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Drug Development and Regulatory Science in China.
    Chen J; Zhao N
    Ther Innov Regul Sci; 2018 Nov; 52(6):739-750. PubMed ID: 29714583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?
    Klein K; Stolk P; Tellner P; Acha V; Montagne S; Stöckert I
    Ther Innov Regul Sci; 2022 Mar; 56(2):366-377. PubMed ID: 35129827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-five years of addressing cutting-edge scientific, policy, and regulatory issues through collaboration: The Forum for Collaborative Research.
    Schaefer R; Ayvaz A; Hoffman CR; Yann M; Rooney Z; Leus M; Mitra S; Miller V;
    Clin Transl Sci; 2024 Oct; 17(10):e70051. PubMed ID: 39425910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UK medicines regulation: responding to current challenges.
    Richards N; Hudson I
    Br J Clin Pharmacol; 2016 Dec; 82(6):1471-1476. PubMed ID: 27580254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "What's Keeping Me Up at Night?" Reflections on the COVID-19 Pandemic in Asia.
    Mundy L; Kearney B
    Int J Technol Assess Health Care; 2022 Jun; 38(1):e51. PubMed ID: 35702950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
    Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
    F1000Res; 2018; 7():111. PubMed ID: 30026923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines.
    Popkin ME; Goese M; Wilkinson D; Finnie S; Flanagan T; Campa C; Clinch A; Teasdale A; Lennard A; Cook G; Mohan G; Osborne MD
    AAPS J; 2022 Sep; 24(6):101. PubMed ID: 36168002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparing for the Next Normal: Transformation in the Role of Medical Affairs Following the COVID-19 Pandemic.
    Ghosh R; Mohanasundaram S; Shetty S; Menon S
    Pharmaceut Med; 2021 Jul; 35(4):197-202. PubMed ID: 34224113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learning From Agility, Partnership and Innovation During the Covid-19 Pandemic: A Perspective From Industry.
    Cárdenas AM; Roger-Dalbert C
    Front Cell Infect Microbiol; 2022; 12():838565. PubMed ID: 35252041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Medicines Agency-Health Technology Assessment Parallel Consultation Platform: An Industry Perspective.
    Khan S; Carter M
    Clin Pharmacol Ther; 2019 Apr; 105(4):822-825. PubMed ID: 30811582
    [No Abstract]   [Full Text] [Related]  

  • 18. Orphan Medicines for Pediatric Use: A Focus on the European Union.
    Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
    Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential Case Management Practices Amidst the Novel Coronavirus Disease 2019 (COVID-19) Crisis: Part 2: End-of-Life Care, Workers' Compensation Case Management, Legal and Ethical Obligations, Remote Practice, and Resilience.
    Tahan HM
    Prof Case Manag; 2020; 25(5):267-284. PubMed ID: 32452940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health crisis: What opportunities for clinical drug research?
    Deplanque D; Cviklinski S; Bardou M; Ader F; Blanchard H; Barthélémy P; David I; D'Ortenzio E; Espérou H; Launay O; Lazarevic M; Lechat P; Lethiec F; Levy Y; Pérol D; Rage V; Roustit M; Thabut G
    Therapie; 2022; 77(1):59-67. PubMed ID: 34973823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.